Abstract

Immunotherapy Considerable advances have been made in engineering T cells for adoptive cell transfer to treat cancer by manipulating the patients' immune system. In a Perspective, Bluestone and Tang discuss the potential for use of regulatory T cells (Tregs) to treat patients with autoimmunity and other diseases that involve pathological inflammation. Preclinical research has provided encouraging results with Treg therapies, and numerous clinical trials have been initiated to test adoptive Treg transfer in patients with, for example, type I diabetes, organ transplant rejection, and amyotrophic lateral sclerosis. Science , this issue p. [154][1] [1]: /lookup/doi/10.1126/science.aau2688

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.